Fig. 2

Visualization of atypical cholangiocyte proliferation derived from HCT in chronic liver injury. a and b Liver samples were collected from healthy controls and patients with liver cirrhosis. HCT was measured by IF of hepatocyte markers (ALB, HNF4α) and cholangiocyte markers (CK19, SOX9). c and d HCT was measured in livers of the WT-NS, WT-TAA, and KO-TAA groups by IF of hepatocyte marker (ALB) and cholangiocyte markers (CK19, SOX9). e and f HCT was measured by IF of hepatocyte marker (ALB) and cholangiocyte markers (CK19, SOX9) in livers of the WT-TAA and WT-TAA + imrecocxib groups (e) and in the WT-TAA and CKO-TAA groups (f). White arrows indicate coexpression or colocalization of hepatocyte and cholangiocyte markers. Scale bars 50μm